清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

A First-in-Human Dose Escalation Clinical Trial of Engineered Natural Killer Cell Therapy in Non-Small Cell Lung Cancer Patients Refractory to Immune Check Point Inhibitors

医学 细胞毒性T细胞 肺癌 免疫学 自然杀伤细胞 内科学 肿瘤科 癌症研究 生物 生物化学 体外
作者
Miguel A. Villalona,Lei Tian,Xiaochen Li,Joycelynne Michelle Palmer,Claudia Aceves,Hans Meisen,Catherine A. Cortez,Timothy Walter Synold,Colt A. Egelston,Jeffrey Bryan VanDeusen,Ivone Bruno,Lei Zhang,Eliezer Romeu-Bonilla,Omer I. Butt,Stephen J. Forman,Michael A. Caligiuri,Jianhua Yu
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 7206-7206
标识
DOI:10.1182/blood-2024-202132
摘要

Background: Tumor reactive or activated-by-cytokine killers (TRACK) are PD-L1+ highly cytolytic natural killer (NK) cells derived from umbilical cord blood NK cells that are engineered to express soluble IL15 (sIL15). sIL15_TRACK NK cells have shown promise in preclinical studies against human non-small cell lung cancer (NSCLC) (PMID: 38572955). Here we demonstrate sIL15_TRACK NK cells traffic to the patients' solid tumor site, survive at the tumor site and retain cytotoxic function at the tumor site. Three of six patients, all with progressive disease at the time of study enrollment, achieved stable disease following the infusions of sIL15_TRACK NK cells. Methods: This first-in-human phase 1 trial (NCT05334329) evaluated the initial safety, tolerability, and preliminary efficacy of unmatched, allogeneic, off-the-shelf sIL15_TRACK NK cells in six patients with advanced, previously treated NSCLC that were relapsed from or refractory to chemotherapy, refractory to immune checkpoint inhibition, and progressing at the time of enrollment. Patients received a standard lymphodepletion regimen (LDR) followed by 4 or 8 weekly infusions of sIL15_TRACK NK cells at one of two dose levels. NK cell persistence and cytotoxic activity were monitored using droplet digital PCR (ddPCR), flow cytometry, and immunofluorescent staining of a tumor biopsy. Results: The sIL15_TRACK NK cell therapy was delivered in the outpatient setting, was well-tolerated without severe adverse events related to the therapy. Common grade 1-2 toxicities included fatigue, nausea, and diarrhea, while grade 3-4 hematologic toxicities were likely related to the standard LDR. Pharmacokinetic studies demonstrated that sIL15_TRACK NK cells were measurable in blood hours after infusion and peak measurements increased weekly, suggesting an absence of host rejection even during the second cycle where cyclophosphamide was administered without fludarabine for the LDR. sIL15_TRACK NK cells were observed in a lung tumor biopsy 7 days following the final infusion, confirming their sustainment and tumor-homing ability. The engineered sIL15_TRACK NK cells express several cell activating receptors (e.g., NKG2D, DNAM-1, and NKp30) that bind to cognate ligands that we show to be expressed on a NSCLC patient biopsy (e.g., MICA/B, CD112, and BAG6, respectively), and retain their cytolytic function following isolation from the lung tumor tissue. At two low doses of cells tested (1.5 × 106 and 4.0 × 106 transduced cells/kg), three out of six patients (50%) achieved disease stabilization as best response on repeat imaging, while the remaining three showed progressive disease. Conclusion: Unmatched, allogeneic, off-the-shelf sIL15_TRACK NK cell therapy demonstrated a favorable safety profile and showed preliminary efficacy in stabilizing disease in a subset of patients with advanced and progressive NSCLC. The ability of engineered sIL15_TRACK NK cells to express activating receptors, home to tumor sites that express their cognate ligands, and retain cytolytic activity after infusion underscores their potential as a novel immunotherapeutic approach in solid tumors. Additional dose escalation cohorts and co-administration with atezolizumab are planned for a second stage of this trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
自由的M完成签到 ,获得积分10
8秒前
悄然飘去完成签到 ,获得积分10
11秒前
甜美忆寒完成签到,获得积分10
21秒前
开心的冬瓜完成签到 ,获得积分10
22秒前
今天很美味完成签到 ,获得积分10
24秒前
24秒前
北北完成签到 ,获得积分10
25秒前
我爱罗完成签到 ,获得积分10
26秒前
sponge完成签到 ,获得积分10
31秒前
airtermis完成签到 ,获得积分10
40秒前
cccp完成签到,获得积分20
40秒前
夕阳下仰望完成签到 ,获得积分10
44秒前
矮小的幻儿完成签到 ,获得积分10
48秒前
lattercomer完成签到 ,获得积分10
53秒前
韩立完成签到 ,获得积分10
59秒前
南风完成签到 ,获得积分10
1分钟前
追寻的凌香完成签到,获得积分10
1分钟前
无限鸣凤完成签到,获得积分10
1分钟前
真实的画板完成签到 ,获得积分10
1分钟前
cccp发布了新的文献求助30
1分钟前
HNO3完成签到,获得积分10
1分钟前
体贴的惜文完成签到,获得积分10
1分钟前
iitj完成签到,获得积分10
1分钟前
ZDU完成签到 ,获得积分10
1分钟前
周立杰完成签到,获得积分10
1分钟前
含糊的青烟完成签到 ,获得积分10
1分钟前
时尚的访琴完成签到 ,获得积分10
1分钟前
miaorunquan完成签到,获得积分0
1分钟前
龙弟弟完成签到 ,获得积分10
1分钟前
王勇1234完成签到 ,获得积分10
1分钟前
henry完成签到 ,获得积分10
1分钟前
优雅的绿蓉完成签到 ,获得积分10
1分钟前
Elaine完成签到 ,获得积分10
1分钟前
小雄完成签到 ,获得积分10
2分钟前
负责的菲鹰完成签到,获得积分10
2分钟前
小幺完成签到 ,获得积分10
2分钟前
冷艳的老四完成签到,获得积分10
2分钟前
此时此刻完成签到 ,获得积分10
2分钟前
溪泉完成签到,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180051
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808628
捐赠科研通 7776034
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557405
邀请新用户注册赠送积分活动 2478998